
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Selecting second-line after FLOT and immunotherapy
Panel recommends anti‑HER2 therapy inclusion, considers T-DXd or FOLFIRI+trastuzumab, and notes timing after FLOT.
Play episode from 18:20
Transcript


